Anteris Technologies Global Corp. (AVR)

Market Cap	534.91M +159.5%
Revenue (ttm)	2.14M -21.1%
Net Income	-84.32M
EPS	-2.56
Shares Out	41.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	734,797
Open	5.74
Previous Close	5.61
Day's Range	5.51 - 5.89
52-Week Range	2.34 - 8.79
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 5, 2026

About AVR

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for s...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Dec 13, 2024
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: AVR
• Website: https://anteristech.com

Financial Performance

In 2024, AVR's revenue was $2.70 million, a decrease of -1.17% compared to the previous year's $2.74 million. Losses were -$76.29 million, 65.8% more than in 2023.